Original Article

Genetic Characterization of Second-Line Drug-Resistant and Extensively Drug-Resistant *Mycobacterium tuberculosis* from the Northern Region of India

Rakesh Yadav¹, Aastha Saini¹, Jureka Mankotia², Rajiv Khaneja³, Priyanka Agarwal¹, Sunil Sethi¹*³

¹Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
²Intermediate Reference Laboratory, Dharampur, Himachal Pradesh, India
³State TB Cell, RNTCP, Sector 34, Chandigarh, India

Article History
Received 14 December 2017
Accepted 26 February 2018

Keywords
Tuberculosis
Cross resistance
Mutation
MAS PCR
DNA sequencing

ARTICLE INFO

ABSTRACT

Rapid detection of drug resistance in *Mycobacterium tuberculosis* is important for the successful treatment of tuberculosis. Fluoroquinolone and aminoglycoside resistance detection by molecular methods becomes more complex due to cross resistance among them. Thus, we aimed to determine cross-resistance and mutations in resistance genes for these drugs. A total of 336 multidrug-resistant tuberculosis (MDR-TB) cases received in Mycobacteriology laboratory were screened for phenotypic drug sensitivity testing for second-line drugs, i.e., ofloxacin, amikacin, kanamycin, and capreomycin. Molecular characterization of resistance was done by DNA sequencing of *gyrA* gene for fluoroquinolones (FQ), and multiplex allele-specific polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (RFLP) of *rrs* gene for aminoglycosides. Of 336 MDR-TB isolates, 12 were extensively drug-resistant tuberculosis and 219 were sensitive to all the drugs tested. Ofloxacin, amikacin, kanamycin, and capreomycin resistance was detected in 30 (10.1%), 25 (7.4%), 27 (8.1%), and 19 (5.6%) cases, respectively. Eight different mutations were detected in *gyrA* gene in ofloxacin-resistant isolates and A1401G nucleotide change in *rrs* gene were seen in 55.6% (152/27), 65.2% (15/23), and 68.4% (13/29) for kanamycin-, amikacin-, and capreomycin-resistant isolates, respectively. Information on second-line drug resistance-associated mutations could potentially be used for development of newer rapid diagnostic tests.

© 2018 Atlantis Press International B.V.

This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

1. INTRODUCTION

Drug-resistant tuberculosis is a major public health problem in developing countries, which also threatens the success of tuberculosis (TB) control programs at the national level. An estimated 300,000 pulmonary multidrug-resistant-TB (MDR-TB) patients were notified in 2014, and more than half of these patients were in India, China, and the Russian Federation. Globally, the success rate of treatment of MDR-TB is only 50%, largely due to high rates of mortality and loss to follow-up. Among the MDR-TB patients, an estimated 9.7% of people have extensively drug-resistant tuberculosis (XDR-TB) [1]. MDR-TB is defined as *Mycobacterium tuberculosis* strain resistant to at least rifampin and isoniazid, and XDR-TB is MDR *M. tuberculosis* and also resistant to one of the second-line injectable drugs (SCID; amikacin, kanamycin, or capreomycin) and a fluoroquinolone. Rapid detection of MDR- and XDR-TB is necessary for the selection of correct treatment regimen and to reduce the transmission of drug-resistant strains [2].

The XDR-TB diagnosis is much more complex than that of MDR-TB due to the absence of rapid and good molecular diagnostic methods. Phenotypic drug sensitivity testing (DST) for second-line drugs, i.e., ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin (fluoroquinolones) and kanamycin, amikacin, and capreomycin (injectable drugs) is reliable and reproducible across various settings. However, the turnaround time of phenotypic DST is in terms of weeks because of the slow growth rate of *M. tuberculosis*. The development of rapid molecular diagnostic test for the detection of second-line resistance needs an accurate knowledge of mutations in the drug-targeted genes from different geographical regions. Molecular diagnosis promises rapid detection of drug resistance, which may be critical in high-burden areas of MDR- and XDR-TB to break the transmission and development of new drug resistance. The molecular mechanisms of drug resistance to second-line antituberculosis drugs have been elucidated [3]. Fluoroquinolones (FQ) resistance in *M. tuberculosis* is mainly due to mutations in quinolone resistance-determining region (QRDR), which is a short nucleotide sequence of the gene *gyrA* and, less frequently, in *gyrB*. The majority of mutations of *gyrA* gene have been correlated with FQ resistance in clinical isolates of *M. tuberculosis*. Resistance to SCID is mainly associated with point mutation in the 16S rRNA gene (*rrs*) at the 1401 position [4,5].
The available molecular methods cannot replace phenotypic DST for second-line antibiotics because there is an incomplete cross-resistance among second-line drugs. The members of different groups of second-line drugs share common mutations in their targeted region, thus making it problematic to differentiate between the cross-resistance among those members. The occurrence of mutations in the targeted regions also varies according to the geographical region. The data from limited studies showed that up to 87% of fluoroquinolone and up to 70% of second-line aminoglycoside resistance is caused by point mutation within the gyrA and rrs gene, respectively [6]. So, this study was planned to understand the cross-resistance and genetically characterize the isolates of this geographical area.

2. MATERIALS AND METHODS

2.1. M. tuberculosis Isolates and Drug Susceptibility Testing

Three hundred and thirty-six (336) pulmonary MDR-TB isolates, which were received between September 2015 to June 2016, were taken from cultures and drug sensitivity testing laboratory, Mycobacteriology Section, Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh (An RNTCP approved center for TB culture and DST). These isolates were received for routine second-line drug testing of M. tuberculosis under the RNTCP program. M. tuberculosis isolates were subcultured and tested for second-line drug sensitivity in BACTEC MGIT 960 (BD Bioscience, Belgium) according to the manufacturer’s instructions (Becton and Dickinson, USA). M. tuberculosis isolates were subjected to second-line drug sensitivity testing using World Health Organization (WHO)-recommended critical concentrations [7] i.e., ofloxacin, 2.0 mg/L; amikacin, 1.0 mg/L; capreomycin, 2.5 mg/L; and kanamycin, 2.5 mg/L (Sigma-Aldrich, USA). Because the observations were made as a part of the national TB control program, a separate ethical clearance was not required.

2.2. Genomic DNA Extraction

One milliliter culture from MGIT was centrifuged, and the pelleted cells were resuspended in 500 µl of distilled H2O and heat inactivated at 95°C for 10 min. Genomic DNA was extracted using a modified cetyltrimethylammonium bromide–sodium chloride method [8].

2.3. PCR Amplification and PCR RFLP

Polymerase chain reaction (PCR) was performed to amplify the partial gyrA and rrs genes of M. tuberculosis. The mutations in gyrA gene were screened by 248 bp PCR amplification followed by DNA sequencing. The Multiplex Allele Specific (MAS) PCR and PCR restriction fragment length polymorphism (RFLP) were used for the detection of A1401G mutation in rrs gene responsible for aminoglycoside resistance in M. tuberculosis [9]. PCR amplification for gyrA was performed in a 25 µl reaction mixture containing 2.5 µl of 10× PCR buffer (Fermentas, Lithuania), 1.5 µl of 10 µM forward (gyr AF) and reverse (gyr AR) primers (Sigma Aldrich, India), 200 µM deoxyribonucleotide triphosphate (dNTP) (Fermentas, Lithuania), 1 U Taq DNA polymerase (Fermentas, Lithuania), and 1 µl genomic DNA. The PCR conditions were as follows: initial denaturation at 95°C for 5 min; 30 cycles including denaturation at 95°C for 45 s, annealing at 58°C for 45 s, and extension at 72°C for 45 s; and last, a final extension at 72°C for 6 min. MAS PCR assay was performed to identify rrs A1401G mutation. PCR assays had a final volume of 25 µl and contained 2.5 µl of 10× PCR buffer (Fermentas, Lithuania), 1.5 U of Taq DNA polymerase (Fermentas, Lithuania), and 50–200 ng of genomic DNA as template. For amplification of rrs, 200 µM of dNTPs (Fermentas, Lithuania), 20 pmol of forward primer RRSF, 5 pmol of internal reverse primer RRSSR1, and 40 pmol of reverse primer RRSSR were used. For PCR RFLP, the same primers RRSF and RRSSR were used followed by the restriction digestion with BmgBI (New England Biolabs, UK). Fragments of 353 and 128 bp were obtained from PCR RFLP of rrs gene showing the wild-type genotype (Fig. 1).

2.4. DNA Sequencing

The gene gyrA of all ofloxacin resistant isolates and the representative samples of rrs gene (5 resistant isolates) were sequenced for mutation analysis. Sequence reactions were carried out in ABI 3130 Genetic Analyzer automated sequencer (Applied Biosystems, USA) following the manufacturer’s instructions. Sequencing primers were identical to the primers used for PCR amplification.

3. RESULTS

3.1. Drug-resistance Patterns among the Clinical Isolates

Among the 336 cases, 215 (63.9%) were male and 121 (36%) were female, and their ages ranged from 12 to 72 years. DST revealed that 229 (68.1%) isolates were susceptible in vitro to all the second-line drugs tested; and 107 (31.8%) were resistant to any of the

Figure 1  PCR RFLP of rrs gene after digestion with BmgBI. Lane 1, 100 bp DNA ladder; Lanes 2 and 3, 353 and 128 bp fragments with wild-type sequence; and Lanes 4 and 5, 481 bp fragments of mutant sequence.
3.2. Cross-resistance of Isolates to SCID

Among the 28 (8.3%) SCID-resistant isolates, kanamycin, amikacin, and capreomycin resistance was found in 27 (81.8%), 23 (68.4%), and 19 (5.6%) isolates, respectively. The cross-resistance among the SCID was found in 25 isolates except in three, which were only resistant to kanamycin. The cross-resistance between three aminoglycosides, i.e., kanamycin, amikacin, and capreomycin was found in 16 isolates and between kanamycin and amikacin in six isolates. Kanamycin and capreomycin or amikacin and capreomycin cross-resistance were found in two and one cases, respectively (Fig. 2).

3.3. Molecular Characterization of Drug Resistance

3.3.1. Ofloxacin resistance

A total of 101 ofloxacin resistant isolates (12 XDR-TB and 89 mono-resistant) were tested for mutations in the partial gyrA gene, including the core region QRDR. The 248 bp amplified PCR product was sequenced, and analysis showed that 92 (91.1%) isolates had a mutation in the gyrA gene and nine (8.9%) isolates did not show any mutation in the target region (Table 1). Codon 94 was found to be the most frequently mutated codon in 55 (54.5%) ofloxacin-resistant isolates. At codon 94, five types of changes were observed: Asp94Gly was found in 34, Asp94Ala in nine, Asp94Asn in six, Asp94Tyr in three, and Asp94His was found in three isolates. At codon 90, only one type of change, i.e., Ala90Val was detected in 24 (23.7%) isolates. Ala90Val/Ser91Pro double change was found in nine isolates, whereas a single change on codon 91 (Ser91Pro) was found in four isolates (Table 1).

3.3.2. SCID resistance

The rrs gene was screened by MAS PCR and confirmed by PCR RFLP for the detection of mutation A1401G. The MAS PCR and PCR RFLP showing double band at 128 and 353 bp were taken as sensitive and single band at 481 resulted in a resistant isolate (Fig. 1). The representative strains were sequenced for the confirmation of results. Of the 27 kanamycin-resistant isolates, 15 (55.6%) had A1401G rrs mutation. The A1401G rrs gene mutation were found in 15/23 (65.2%) amikacin-resistant strains and 13/19 (68.4%) capreomycin-resistant strains (Table 1). All the sensitive strains were also screened for the A1401G mutation, but none of the kanamycin- and amikacin-sensitive strains were found to be mutated at the 1401 codon. Two capreomycin-sensitive strains resistant to amikacin and kanamycin had mutations at the 1401 codon.

4. DISCUSSION

Rapid detection of drug resistance by molecular methods could be of great value in aiding the timely administration of appropriate antibiotics to MDR-TB/XDR-TB patients. In this study, drug resistance pattern of second-line antibiotics and drugs tested. Of the 107 drug-resistant isolates, 12 (3.6%) were found to be XDR-TB. Overall, 89 (26.5%) isolates were mono-resistant to ofloxacin and none to kanamycin, amikacin, and capreomycin. Any resistance to ofloxacin, kanamycin, amikacin, and capreomycin was found in 101 (30.1%), 27 (8%), 23 (6.8%), and 19 (5.6%) isolates, respectively. Among 12 (3.6%) XDR-TB isolates, three were resistant to ofloxacin and kanamycin and another three were resistant to ofloxacin, kanamycin, amikacin, and capreomycin. Four isolates were resistant to ofloxacin, amikacin, and kanamycin, one was resistant to ofloxacin, amikacin, and capreomycin, and yet another isolate was resistant to ofloxacin, kanamycin, and capreomycin.

Figure 2  Cross-resistance of MDR TB isolates to second-line injectable drugs

Table 1  Mutation profiles of resistant genes gyrA (ofloxacin) and rrs (kanamycin, amikacin, and capreomycin) for resistant isolates

| Drug       | Phenotype (No.) | No. | Mutation | Codons                  |
|------------|----------------|-----|----------|-------------------------|
| Ofloxacin  | Resistant (101) | 34  | Asp94Gly | GAC 94 GGC              |
|            |                | 9   | Asp94Ala | GAC 94 GCC              |
|            |                | 6   | Asp94Asn | GAC 94 AAC              |
|            |                | 3   | Asp94Tyr | GAC 94 TAC              |
|            |                | 3   | Asp94His | GAC 94 CAC              |
|            |                | 24  | Ala90Val | GCG 90 GTG              |
|            |                | 9   | Ala90Val/| TCG 91 CCG              |
|            |                |     | Ser91Pro | Ser91Pro                 |
| Kanamycin  | Resistant (27)  | 15  | A1401G   | A1401G                  |
|            |                | 12  | Wild Type| A1401G                  |
| Amikacin   | Resistant (23)  | 15  | A1401G   | A1401G                  |
|            |                | 8   | Wild Type| A1401G                  |
| Capreomycin| Resistant (19)  | 13  | A1401G   | A1401G                  |
|            |                | 6   | Wild Type| A1401G                  |
mutations in their targets were characterized in MDR-TB isolates from North India. Among the second-line antibiotics, the molecular mechanism of drug resistance is the most completely understood for fluoroquinolone as compared with that of others. Fluoroquinolones resistance in *M. tuberculosis* has been predominantly attributed to *gyrA* mutations [5,10]. In our study, the phenotypic and genotypic concordance was found to be 91.1% for oxolinic acid resistant. Of the oxolinic acid-resistant isolates, 92 (91.1%) had mutations in the QRDR region of the *gyrA* gene, whereas nine (8.9%) had none. Mutations at *gyrA* codons 90, 91, or 94 were the most common in previous studies [3–5,11], and we found that 79 (78.2%) isolates had point mutations at two major codons, i.e., 94 and 90 of the core QRDR of the *gyrA* gene. The most frequent mutation found was A694Gly in 34 (33.7%) isolates, followed by Ala90Val in 24 (23.7%). Double mutation GCG-GTG/GAC-GGC was detected in nine (8.9%) isolates. Previous studies reporting mutations have shown that in Indian isolates the most common mutation of the *gyrA* gene is at codon 94, followed by codons 90 and 91 [12,13]. In this study, however, we found no isolates harboring mutations at codon 88, but nine isolates were detected with a double mutation in the QRDR region. A rare mutation A694His was detected in three isolates that was resistant to oxolinic acid. For SCID, the *rrs* A1401G single nucleotide polymorphism has been considered a sensitive marker for resistance, because it accounted for high-level resistance to the various drugs mentioned. Approximately 30–90% of aminoglycoside-resistant strains harbor this mutation; thus, it can be used as a surrogate marker for the detection of resistance to amikacin and kanamycin [9,14,15]. The other mutations in *rrs* gene are poor markers due to their presence in susceptible strains [16]. In our study, *rrs* mutations in aminoglycoside-resistant isolates were more common specifically at the residue 1401. The nucleotide change in *rrs* gene was seen in 55.6% (15/27), 65.2% (15/23), and 68.4% (13/29) for kanamycin-, amikacin-, and capreomycin-resistant strains, respectively. No kanamycin- and amikacin-sensitive strains had mutations on this site. Two capreomycin-sensitive isolates had mutations on this site. Two capreomycin-sensitive isolates had mutations on this site. Two capreomycin-sensitive isolates had mutations on this site. Two capreomycin-sensitive isolates had mutations on this site.

Treatment outcome of MDR-TB cases is poor because it relies on second-line drugs that are less-potent and more toxic, and owing to the emergence of drug resistance. For better management of MDR-TB, we need to check the activity of new compounds that can give better results [17,18]. To increase the sensitivity and specificity of molecular diagnostics for the detection of XDR-TB, we need an understanding of the frequency of different mutations in the drug-targeted region and their geographical distribution. This study characterizes mutations conferring resistance to fluoroquinolones and SCID at the common target loci in *M. tuberculosis* isolates from North India, and enhances our understanding of the geographic distribution of resistant alleles from this region. Such data may be valuable for the development of newer, rapid, and reliable molecular approaches for the detection of XDR-TB in clinical isolates of *M. tuberculosis*.

**ACKNOWLEDGMENTS**

The financial, administrative, and technical support of the Department of Medical Microbiology, PGIMER, Chandigarh and Revised National Tuberculosis Control Program is acknowledged.

**CONFLICTS OF INTEREST**

All authors declared no conflicts of interest.

**REFERENCES**

[1] World Health Organization. Global tuberculosis control report 2014. Geneva, Switzerland: World Health Organization; 2014. Available from: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf

[2] Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516–28.

[3] Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, et al. Cloning and nucleotide sequence of *Mycobacterium tuberculosis* *gyrA* and *gyrB* genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773–80.

[4] Pitaksajakul P, Wongwit W, Punprasit W, Eampokalap B, Peacock S, Ramasoota P. Mutations in the *gyrA* and *gyrB* genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health 2005;36 Suppl 4:228–37.

[5] Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portais F, et al. Fluoroquinolone resistance in *Mycobacterium tuberculosis* and mutations in *gyrA* and *gyrB*. Antimicrob Agents Chemother 2009;53:4498–500.

[6] Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, Chan RC. Multiplex PCR amplifier conformation analysis for rapid detection of *gyrA* mutations in fluoroquinolone-resistant *Mycobacterium tuberculosis* clinical isolates. Antimicrob Agents Chemother 2004;48:596–601.

[7] World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva: World Health Organization; 2008. Available from: http://apps.who.int/iris/bitstream/10665/70500/1/WHO_HTM_TB_2008.392_eng.pdf

[8] van Soolingen D, Hermans PW, de Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in *Mycobacterium tuberculosis* complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991;29:2578–86.

[9] Evans J, Segal H. Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in *Mycobacterium tuberculosis*. J Antimicrob Chemother 2010;65:897–900.

[10] Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. *gyrA* mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of *Mycobacterium tuberculosis*. J Antimicrob Chemother 2012;67:1088–93.

[11] Lee AS, Tang LL, Lim IH, Wong SY. Characterization of pyrazinamide and oxolinic acid resistance among drug resistant *Mycobacterium tuberculosis* isolates from Singapore. Int J Infect Dis 2002;6:48–51.

[12] Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V, et al. Prevalence of *gyrA* and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of *Mycobacterium tuberculosis* and their relationship with MIC of ofloxacin. J Antimicrob Chemother (Tokyo) 2015;68:63–6.
[13] Singhal R, Reynolds PR, Marola JL, Epperson LE, Arora J, Sarin R, et al. Sequence analysis of fluoroquinolone resistance-associated genes gyrA and gyrB in clinical Mycobacterium tuberculosis isolates from patients suspected of having multidrug-resistant tuberculosis in New Delhi, India. J Clin Microbiol 2016;54:2298–305.

[14] Ajbani K, Rodrigues C, Shenai S, Mehta A. Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India. J Clin Microbiol 2011;49:1588–90.

[15] Perdigão J, Macedo R, Malaquias A, Ferreira A, Brum L, Portugal I. Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother 2010;65:224–7.

[16] Georgiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012;7:e33275.

[17] Fassihi A, Azadpour Z, Delbari N, Saghaie L, Memarian HR, Sabet R, et al. Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides. Eur J Med Chem 2009;44:3253–8.

[18] Khoshneviszadeh M, Edraki N, Javidnia K, Alborzi A, Pourabbas B, Mardaneh J, et al. Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents. Bioorg Med Chem 2009;17:1579–86.